Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Evaluation of Tumor Viability for Primary and Bone Metastases in Metastatic Castration-Resistant Prostate Cancer Using Whole-Body Magnetic Resonance Imaging.

Iwamura H, Kaiho Y, Ito J, Anan G, Satani N, Matsuura T, Tamura R, Murakami K, Koyama K, Sato M.

Case Rep Urol. 2018 Jun 7;2018:4074378. doi: 10.1155/2018/4074378. eCollection 2018.

2.

Rationale for Modernising Imaging in Advanced Prostate Cancer.

Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, Sala E, Fanti S, Vargas HA, Petralia G, Schlemmer HP, Tombal B, de Bono J.

Eur Urol Focus. 2017 Apr;3(2-3):223-239. doi: 10.1016/j.euf.2016.06.018. Epub 2016 Jul 15. Review.

3.

Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.

Larbi A, Dallaudière B, Pasoglou V, Padhani A, Michoux N, Vande Berg BC, Tombal B, Lecouvet FE.

Prostate. 2016 Aug;76(11):1024-33. doi: 10.1002/pros.23196. Epub 2016 May 16.

PMID:
27197649
4.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
5.

Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study.

Balogova S, Zakoun JB, Michaud L, Khalil A, Tassart M, Esteso A, Kerrou K, Huchet V, Carette MF, Lotz JP, Talbot JN.

Clin Nucl Med. 2014 Nov;39(11):951-9. doi: 10.1097/RLU.0000000000000562.

PMID:
25140552
6.

Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.

Conde-Moreno AJ, Herrando-Parreño G, Muelas-Soria R, Ferrer-Rebolleda J, Broseta-Torres R, Cozar-Santiago MP, García-Piñón F, Ferrer-Albiach C.

Clin Transl Oncol. 2017 May;19(5):553-561. doi: 10.1007/s12094-016-1563-4. Epub 2016 Oct 31.

PMID:
27796820
7.

METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer.

Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, Sala E, Schlemmer HP, Petralia G, Vargas HA, Fanti S, Tombal HB, de Bono J.

Eur Urol. 2017 Jan;71(1):81-92. doi: 10.1016/j.eururo.2016.05.033. Epub 2016 Jun 14.

8.

Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.

Hanyok BT, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Posadas EM, Freedland SJ.

Cancer. 2016 Jan 15;122(2):222-9. doi: 10.1002/cncr.29748. Epub 2015 Oct 20.

9.

Clinical value of whole-body magnetic resonance diffusion weighted imaging on detection of malignant metastases.

Li C, Liu ZS, Du XM, He L, Chen J, Wang W, Sun F, Du F, Luo ZG, Xue ZL, Zhao Y, Zhou CW.

Chin Med Sci J. 2009 Jun;24(2):112-6.

PMID:
19618609
10.

Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.

Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD.

J Nucl Med. 2012 Nov;53(11):1670-5. doi: 10.2967/jnumed.112.105007. Epub 2012 Sep 14.

11.

A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.

Iwamura H, Hatakeyama S, Tanaka Y, Tanaka T, Tokui N, Yamamoto H, Imai A, Yoneyama T, Hashimoto Y, Koie T, Yoshikawa K, Ohyama C.

BMC Res Notes. 2014 Jan 29;7:64. doi: 10.1186/1756-0500-7-64.

12.

Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT.

Schmidt GP, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR, Reiser MF, Baur-Melnyk A.

Eur Radiol. 2007 Apr;17(4):939-49. Epub 2006 Sep 2.

PMID:
16951929
13.

Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.

Jacobs MA, Macura KJ, Zaheer A, Antonarakis ES, Stearns V, Wolff AC, Feiweier T, Kamel IR, Wahl RL, Pan L.

Acad Radiol. 2018 Nov;25(11):1405-1414. doi: 10.1016/j.acra.2018.02.010. Epub 2018 Apr 4.

14.

The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer.

Kosmin M, Makris A, Joshi PV, Ah-See ML, Woolf D, Padhani AR.

Eur J Cancer. 2017 May;77:109-116. doi: 10.1016/j.ejca.2017.03.001. Epub 2017 Apr 5.

PMID:
28390297
15.

Whole-Body MRI with Diffusion-Weighted Imaging in Bone Metastases: A Narrative Review.

Stecco A, Trisoglio A, Soligo E, Berardo S, Sukhovei L, Carriero A.

Diagnostics (Basel). 2018 Jul 9;8(3). pii: E45. doi: 10.3390/diagnostics8030045. Review.

16.

Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer.

McKay RR, Zukotynski KA, Werner L, Voznesensky O, Wu JS, Smith SE, Jiang Z, Melnick K, Yuan X, Kantoff PW, Montgomery B, Balk SP, Taplin ME.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):325-31. doi: 10.1038/pcan.2014.28. Epub 2014 Aug 5.

17.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

PMID:
27591931
18.

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.

Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K.

Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8.

PMID:
29326030
19.

Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.

Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin ME, Taub JM, Herman B, Higano CS, Doot RK, Hartfeil D, Febbo PG, Mankoff DA.

J Nucl Med. 2015 Mar;56(3):354-60. doi: 10.2967/jnumed.114.146936. Epub 2015 Jan 29.

20.

Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer.

Eschmann SM, Pfannenberg AC, Rieger A, Aschoff P, Müller M, Paulsen F, Anastasiadis A, Claussen CD, Bares R, Schlemmer HP.

Nuklearmedizin. 2007;46(5):161-8; quiz N47-8.

PMID:
17938748

Supplemental Content

Support Center